{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:14:12Z","timestamp":1783757652131,"version":"3.55.0"},"reference-count":39,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2026,7]]},"abstract":"\n Background<\/jats:title>\n Long-term combination anti-tuberculosis regimens may lead to various types and severities of adverse drug reactions, potentially resulting in treatment discontinuation, interruption, or prolonged therapy.<\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n Considering the lengthy duration of anti-tuberculosis combination regimens, it is crucial to monitor adverse drug reactions occurring during such treatment. This is the first hospital-based study conducted in western China to report adverse drug reactions and assess their prevalence and impact among children with tuberculosis receiving first-line anti-tuberculosis therapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective study was conducted on registered tuberculosis cases at the Children's Hospital of Chongqing Medical University from 2014 to 2023. Data on demographic characteristics, treatment regimens, and adverse drug reactions were collected and evaluated. Statistical methods were used to analyze factors associated with adverse drug reactions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 546 patients receiving anti-tuberculosis therapy, adverse drug reactions were reported in 476 (87.18%). Hyperuricemia was the most common adverse drug reaction (44.26%), followed by elevated liver enzymes without jaundice and elevated bile acids (10.38%) and leukopenia (8.31%). Most adverse drug reactions occurred within the first month of treatment (51.48%), whereas 33.44% persisted for >6 months. Pyrazinamide was the most frequently suspected causative drug (7.47%). Univariate analysis showed significantly higher adverse drug reaction rates among children aged 11\u201318 years, those with severe tuberculosis, those receiving the isoniazid\u2009+\u2009rifampicin\u2009+\u2009pyrazinamide\u2009+\u2009ethambutol\u2009+\u2009linezolid regimen, those on a recommended dose of rifampicin, and those receiving a high dose of pyrazinamide (\n p<\/jats:italic>\n \u2009<\u20090.05). Logistic regression identified age (odds ratio = 1.640, 95% confidence interval: 1.127\u20132.388,\n p<\/jats:italic>\n \u2009=\u20090.010) and the isoniazid\u2009+\u2009rifampicin\u2009+\u2009pyrazinamide\u2009+\u2009ethambutol\u2009+\u2009levofloxacin regimen (odds ratio = 0.210, 95% confidence interval: 0.048\u20130.932,\n p<\/jats:italic>\n \u2009=\u20090.040) as factors that reduced the odds of adverse drug reactions.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n A high occurrence rate of adverse drug reactions was observed in children undergoing anti-tuberculosis treatment. Timely recognition and management of adverse drug reactions is essential in this patient population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/03000605261463702","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:39:46Z","timestamp":1783582786000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-tuberculosis drug treatment and adverse reactions in 546 children with tuberculosis in Chongqing, China: A 10-year retrospective study"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5407-6322","authenticated-orcid":false,"given":"Xinxue","family":"Wang","sequence":"first","affiliation":[{"name":"Children's Hospital of Chongqing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Xu","sequence":"additional","affiliation":[{"name":"Children's Hospital of Chongqing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"613","article-title":"Interpretation of the World Health Organization's Global Tuberculosis Report 2025","volume":"6","author":"Yan Q","year":"2025","unstructured":"Yan Q, Tao L, Wenbin M, et al. Interpretation of the World Health Organization's Global Tuberculosis Report 2025. J Tuberculosis and Lung Dis 2025; 6: 613\u2013623. (In Chinese).","journal-title":"J Tuberculosis and Lung Dis"},{"key":"e_1_3_3_3_2","volume-title":"Global tuberculosis report 2025","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. Global tuberculosis report 2025. World Health Organization, 2025."},{"key":"e_1_3_3_4_2","first-page":"641","volume":"39","author":"Chinese Antituberculosis Association, Pediatric Tuberculosis Committee & the Society of Tuberculosis, Chinese Medical Association, et al. Expert consensus on the treatment of drug susceptible tuberculosis in children and adolescents","year":"2024","unstructured":"Chinese Antituberculosis Association, Pediatric Tuberculosis Committee & the Society of Tuberculosis, Chinese Medical Association, et al. Expert consensus on the treatment of drug susceptible tuberculosis in children and adolescents. Chin J Appl Clin Pediatr 2024; 39: 641\u2013645. (In Chinese).","journal-title":"Chin J Appl Clin Pediatr"},{"key":"e_1_3_3_5_2","first-page":"173","article-title":"Review of anti-tuberculosis drug treatment and analysis of adverse reactions in pulmonary tuberculosis patients","volume":"20","author":"Suhong H","year":"2023","unstructured":"Suhong H. Review of anti-tuberculosis drug treatment and analysis of adverse reactions in pulmonary tuberculosis patients. J North Pharm 2023; 20: 173\u2013175. (In Chinese).","journal-title":"J North Pharm"},{"key":"e_1_3_3_6_2","first-page":"1059","article-title":"Automatic monitoring of adverse drug reaction of anti-tuberculosis and analysis of influencing factors","volume":"40","author":"Kai Z","year":"2024","unstructured":"Kai Z, Xiao-qin LU, Zhi D. Automatic monitoring of adverse drug reaction of anti-tuberculosis and analysis of influencing factors. Chin J Clin Pharmacol 2024; 40: 1059\u20131062. (In Chinese).","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_3_7_2","article-title":"Incidence of side effects of antituberculosis drugs and their related factors in northern Iran: a retrospective cohort study","volume":"19","author":"Kheradmand M","year":"2024","unstructured":"Kheradmand M, Afshari M, Aarabi M, et al. Incidence of side effects of antituberculosis drugs and their related factors in northern Iran: a retrospective cohort study. GMS Hyg Infect Control 2024; 19: Doc27.","journal-title":"GMS Hyg Infect Control"},{"key":"e_1_3_3_8_2","first-page":"117","article-title":"Retrospective analysis of 376 cases of adverse reactions to antituberculosis drug","volume":"42","author":"Li N","year":"2021","unstructured":"Li N, Chen J, Luo J, et al. Retrospective analysis of 376 cases of adverse reactions to antituberculosis drug. J Kunming Med Univ 2021; 42: 117\u2013121.","journal-title":"J Kunming Med Univ"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038273"},{"key":"e_1_3_3_10_2","first-page":"191","article-title":"Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the tamale teaching hospital, Ghana","volume":"38","author":"Amalba A","year":"2021","unstructured":"Amalba A, Bugri AA. Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the tamale teaching hospital, Ghana. Pan Afr Med J 2021; 38: 191.","journal-title":"Pan Afr Med J"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2020.01.011"},{"key":"e_1_3_3_12_2","first-page":"45","article-title":"Common adverse reactions and intervention strategies during drug treatment in adolescent patients with pulmonary tuberculosis","volume":"30","author":"A'fang Y","year":"2024","unstructured":"A'fang Y, Rui G. Common adverse reactions and intervention strategies during drug treatment in adolescent patients with pulmonary tuberculosis. Chin J Drug Abuse Prev Treat 2024; 30: 45\u201347\u2009+\u200955. (In Chinese).","journal-title":"Chin J Drug Abuse Prev Treat"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18147574"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmy.ijmy_75_20"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1183-4"},{"key":"e_1_3_3_16_2","first-page":"1081","article-title":"Mining and analysis of risk signals of hepatobiliary system adverse events caused by anti-tuberculosis drugs based on FAERS","volume":"20","author":"Wang Y","year":"2023","unstructured":"Wang Y, Jia LI, Qiu-yi HE, et al. Mining and analysis of risk signals of hepatobiliary system adverse events caused by anti-tuberculosis drugs based on FAERS. Anti-Infect Pharm 2023; 20: 1081\u20131088. (In Chinese).","journal-title":"Anti-Infect Pharm"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.21315\/mjms2018.25.5.10"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236109"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-626OC"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.01.014"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.813682"},{"key":"e_1_3_3_22_2","first-page":"628","article-title":"Meta-analysis on risk factors for antituberculosis drug-induced liver injury (ADILI) in Chinese patients","volume":"46","author":"Yong-Hong L","year":"2021","unstructured":"Yong-Hong L, Hong-en L, Shi-xin L, et al. Meta-analysis on risk factors for antituberculosis drug-induced liver injury (ADILI) in Chinese patients. Chin J Antibiot 2021; 46: 628\u2013633. (In Chinese).","journal-title":"Chin J Antibiot"},{"key":"e_1_3_3_23_2","first-page":"67","article-title":"Logistic regression analysis of risk factors of antituberculosis drug-induced liver injury","volume":"39","author":"Xue-min Y","year":"2019","unstructured":"Xue-min Y, Bao-rong S, Peng-yuan L, et al. Logistic regression analysis of risk factors of antituberculosis drug-induced liver injury. Chin J Hospital Pharm 2019; 39: 67\u201371. (In Chinese).","journal-title":"Chin J Hospital Pharm"},{"key":"e_1_3_3_24_2","first-page":"1850","article-title":"Analysis of adverse reactions report of anti-tuberculosis drugs","volume":"17","author":"Yanrong L","year":"2022","unstructured":"Yanrong L, Aijie Z, Nan Y, et al. Analysis of adverse reactions report of anti-tuberculosis drugs. China Medicine 2022; 17: 1850\u20131853. (In Chinese).","journal-title":"China Medicine"},{"key":"e_1_3_3_25_2","first-page":"465","article-title":"Clinical analysis of hypothyroidism after anti-tuberculosis treatment in patients with multidrug-resistant tuberculosis","volume":"42","author":"Ben-nan Z","year":"2020","unstructured":"Ben-nan Z, Da-feng L, Ya-ling L, et al. Clinical analysis of hypothyroidism after anti-tuberculosis treatment in patients with multidrug-resistant tuberculosis. Chin J Antituberc 2020; 42: 465\u2013471. (In Chinese).","journal-title":"Chin J Antituberc"},{"key":"e_1_3_3_26_2","article-title":"Cycloserine-Induced psychosis: a case report","volume":"17","author":"Raikar SR","year":"2025","unstructured":"Raikar SR, Sreeraj G, Sneha S, et al. Cycloserine-Induced psychosis: a case report. Cureus. 2025; 17:e77078.","journal-title":"Cureus"},{"key":"e_1_3_3_27_2","article-title":"Drug reaction with eosinophilia and systemic symptoms-associated perimyocarditis after initiation of anti-tuberculosis therapy: a case report","volume":"15","author":"Kong D","year":"2023","unstructured":"Kong D, Dixit K, Konje S, et al. Drug reaction with eosinophilia and systemic symptoms-associated perimyocarditis after initiation of anti-tuberculosis therapy: a case report. Cureus 2023; 15: e37399.","journal-title":"Cureus"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpam.2020.03.012"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2013(03)OA08"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.16.2114"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.03.031"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI155851"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy627"},{"key":"e_1_3_3_34_2","volume-title":"WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents [Internet]","unstructured":"WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents [Internet]. Geneva: World Health Organization; 2022. PubMed: 35404556."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70005"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtldopen.25.0309"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtldopen.25.0446"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtldopen.25.0365"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-023-04943-9"},{"key":"e_1_3_3_40_2","first-page":"239","article-title":"Hepatites t\u00f3xicas: revis\u00e3o da literatura","volume":"4","author":"Matos LC","year":"2005","unstructured":"Matos LC, Martins B. Hepatites t\u00f3xicas: revis\u00e3o da literatura. Med-Interna 2005; 4: 239\u2013258.","journal-title":"Med-Interna"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261463702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605261463702","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261463702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T07:52:03Z","timestamp":1783756323000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605261463702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/03000605261463702"],"URL":"https:\/\/doi.org\/10.1177\/03000605261463702","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"03000605261463702"}}